pairingsPairing
Amivantamab + lazertinib (first-line EGFR NSCLC)
Blocking EGFR from inside (a pill) and outside (an antibody that also blocks MET) beat osimertinib and added more than a year of survival.
MARIPOSA: PFS 23.7 vs 16.6 months (HR 0.70); OS HR 0.75, median >12 months longer (2025). Cost is more toxicity (rash, paronychia, VTE, infusion reactions) and IV visits; subcutaneous amivantamab (2025) eases the latter.
Rationale
Lazertinib blocks intracellular EGFR signalling while amivantamab blocks EGFR and MET extracellularly and recruits immune effectors, pre-empting the MET-amplification and C797S escape routes.
Evidence
Phase 3 with OS benefit.
Pages like this
not linked directly; found by shared links- PersonDae Ho Lee
Shares Lazertinib, MARIPOSA, Amivantamab, MET.
- PersonByoung Chul Cho
Shares Lazertinib, MARIPOSA, Amivantamab, MET.
- TermEGFR exon 19 deletion & L858R
Shares Lazertinib, Amivantamab, Osimertinib, EGFR.
- IdeaAdd a drug when the blood test turns, without stopping the one that works
Shares Amivantamab, MET, Osimertinib, EGFR.
- IdeaAdd the second drug on day one when the escape route is predictable
Shares Amivantamab, MET, Osimertinib, EGFR.
- InstitutionShanghai Chest Hospital
Shares Amivantamab, MET, Osimertinib, EGFR.
- TrialLAURA
Shares Osimertinib, EGFR, Non-small-cell lung cancer.
- PairingEGFR TKI → ADC on progression
Shares Amivantamab, Osimertinib, Non-small-cell lung cancer.